Life Sciences

  • March 11, 2026

    New Wyoming Abortion Law Faces Familiar Legal Challenge

    Just a day after it was signed into law, Wyoming's new anti-abortion law triggered a legal challenge from the same health clinic that successfully sued over the state's previous abortion limits.

  • March 11, 2026

    La. Fights Dismissal Bid In Abortion Regulation Dispute

    The state of Louisiana urged a federal court to deny motions by GenBioPro Inc. and Danco Laboratories seeking dismissal of its suit challenging federal regulation on mail-order abortion drugs, arguing it has established harms stemming from the regulations.

  • March 11, 2026

    Insulin Makers Ask Justices To Review Collusion Case

    Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP have told the U.S. Supreme Court that a ruling reviving a case over insulin drug costs undermines key rules meant to weed out improper antitrust claims.

  • March 11, 2026

    Pharma Co. Says Ex-Director Using Trade Secrets At New Job

    A specialty infusion therapy pharmacy has accused a former director of contracts of taking valuable trade secrets with her on her way out to work for a rival company.

  • March 11, 2026

    Bayer Sees 'Light At The End Of The Tunnel' In Roundup Suits

    After more than a decade and tens of thousands of cases, a recent settlement announcement and a high-stakes high court hearing may finally give the makers of the weedkiller Roundup an off-ramp in seemingly never-ending litigation.

  • March 11, 2026

    Pa. Justices Doubtful Law Unclear In AG-DA Opioid Deal Row

    Multiple Pennsylvania Supreme Court justices on Wednesday doubted a state law was ambiguous about whether the attorney general could step in and settle claims brought by county-level district attorneys, as he had in a multistate settlement with opioid companies.

  • March 11, 2026

    Anthem Beats Lab's $1.9M ERISA Payment Demand

    Anthem Blue Cross Blue Shield of Connecticut has prevailed in a medical laboratory's $1.9 million contract and ERISA lawsuit over allegations the insurer refused to pay for out-of-network tests.

  • March 11, 2026

    Minn. Lawmakers Advance Medical Psilocybin Bill

    Minnesota lawmakers this week advanced a bipartisan bill to create a regulated medical program for psilocybin, the active ingredient in psychoactive mushrooms.

  • March 11, 2026

    MoFo Private Equity Atty Joins Greenberg Traurig In Miami

    Greenberg Traurig LLP announced Wednesday that a Miami-based private equity attorney has joined the firm's corporate practice from Morrison Foerster LLP.

  • March 11, 2026

    Biomedical Co. Settles Trade Secrets Case Against Ex-Worker

    Biomedical company Skye Orthobiologics and a former employee have informed a California federal judge that they have settled a case accusing the ex-employee of breaching fiduciary duties by leveraging Skye's proprietary information.

  • March 11, 2026

    Investor Urges Revival Of Armistice Insider Trading Claims

    The Delaware Supreme Court has heard arguments over whether a hedge fund that traded tens of millions of dollars' worth of stock can face insider trading liability under state law after its board designee allegedly received confidential company information, with an Aytu BioPharma shareholder urging the court to revive claims against healthcare investor Armistice Capital.

  • March 10, 2026

    Justices Advised To Keep Law Clear In 'Skinny Label' Case

    Several intellectual property groups have urged the U.S. Supreme Court to use a case involving "skinny labels" on generic drugs to set clear guidelines on what constitutes induced patent infringement, saying the outcome has implications beyond pharmaceuticals.

  • March 10, 2026

    J&J Unit Wins Sanction In Talc Libel Case

    A Virginia federal judge on Tuesday issued sanctions against a doctor being sued by a Johnson & Johnson unit over an article linking mesothelioma with talc products, saying that a jury will be told that he deleted emails about the article when he was legally obligated to keep them.

  • March 10, 2026

    5th Circ. Revives J&J Sales Rep's Wage Dispute

    A Texas federal court did not take into consideration relevant factors to determine whether a former Johnson & Johnson sales representative's failure to retain local counsel in his wage and hour suit represented excusable neglect, the Fifth Circuit ruled on Tuesday.

  • March 10, 2026

    Sanofi Says Judge Botched Insulin Device Patent Listings

    Sanofi-Aventis sparred with drug wholesalers over a Massachusetts federal magistrate judge's pronouncements that the parties should go to trial on claims the pharmaceutical giant used improper insulin device patent listings to anticompetitively protect the blockbuster Lantus insulin pen from competition.

  • March 10, 2026

    Lab's Aetna Payment Suit Survives, But With Deep Cuts

    A Connecticut federal judge ruled Aetna and its parent company, CVS Health Corp., must face a pared down lawsuit from a medical laboratory alleging it is owed $20.6 million in unpaid invoices.

  • March 10, 2026

    FDA To Consider Coffee, 'Spice' E-Cig Flavors

    The U.S. Food and Drug Administration on Monday indicated that it would be willing to consider e-cigarette flavors shown to be less attractive to youth, like coffee or spices, a move that's come under fire from public health advocates.

  • March 10, 2026

    CVS Can't 'Relitigate' Price-Gouging Class Cert.

    A Rhode Island federal judge refused to narrow the certified classes of health plans alleging CVS schemed with pharmacy benefit managers to overcharge insured health plans for generic drugs, finding that PBM Express Scripts' refusal to produce its contracts changes nothing about how the classes will be assessed.

  • March 10, 2026

    Former Conn. Prosecutor Can Stay On Generic-Drug Case

    Connecticut's former assistant attorney general can continue to represent insurers Humana and Molina Healthcare Inc. in multidistrict litigation over alleged price-fixing of generic drugs, after the Pennsylvania federal judge overseeing the case agreed Monday with a report that the attorney has no information that had not already been shared.

  • March 10, 2026

    Medtronic Expands Vascular Device Line With $550M Deal

    Medtronic said Tuesday it will acquire privately held Scientia Vascular for about $550 million, strengthening its portfolio of devices used to treat stroke and other neurovascular conditions.

  • March 10, 2026

    J&J Opposes Beasley Allen Reinstatement Bid In NJ Talc Fight

    Johnson & Johnson is urging the New Jersey Supreme Court to not take the "extraordinary step" of intervening in an appellate panel ruling that disqualified Beasley Allen from representing hundreds of women in product liability litigation against the pharmaceutical giant after the Georgia-based firm "knowingly collaborated" with a former Johnson & Johnson outside counsel.

  • March 09, 2026

    Texas AG Gets Temporary Ban On Chest Binder Sales

    A Texas state judge has issued a temporary restraining order against a New York-based online retailer of undergarments and chest binders for young women and teens from selling its clothing in the Lone Star State.

  • March 09, 2026

    Abortion Rights Group, SD Agree to End Gas Station Ads Row

    An abortion rights group can no longer post advertisements at gas stations in South Dakota that promote abortion care, the South Dakota attorney general's office announced on Monday, saying that the group and the state have reached an agreement in a pair of lawsuits over the advertising campaign. 

  • March 09, 2026

    Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together

    Novo Nordisk A/S will start selling its GLP-1 medications on Hims & Hers Health Inc.'s platform as part of a deal that resolves the pharmaceutical company's patent infringement lawsuit against the telehealth provider, the companies announced Monday.

  • March 09, 2026

    Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says

    Brass of Ultragenyx Pharmaceutical Inc. are facing shareholder derivative claims they caused the company to overstate prospects for a drug to treat a bone disease, hurting investors and opening the company up to liability when its share prices fell following disappointing clinical trial news.

Expert Analysis

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.